Skip Navigation
American College of Physicians Logo
  • Subscribe
  • Submit a Manuscript
  • Sign In
    Sign in below to access your subscription for full content
    INDIVIDUAL SIGN IN
    Sign In|Set Up Account
    You will be directed to acponline.org to register and create your Annals account
    INSTITUTIONAL SIGN IN
    Open Athens|Shibboleth|Log In
    Annals of Internal Medicine
    SUBSCRIBE
    Subscribe to Annals of Internal Medicine.
    You will be directed to acponline.org to complete your purchase.
Annals of Internal Medicine Logo Menu
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives
  • Author Info
Advanced Search
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Editorials |7 July 2015

PCSK9 Inhibitors: A New Era in Lipid-Lowering Treatment? Free

Miguel Cainzos-Achirica, MD; Seth S. Martin, MD, MHS; John E. Cornell, PhD; Cynthia D. Mulrow, MD, MSc; Eliseo Guallar, MD, DrPH

Miguel Cainzos-Achirica, MD
From Johns Hopkins Medical Institutions, Baltimore, Maryland; University of Texas Health Science Center, San Antonio, Texas; American College of Physicians, Philadelphia, Pennsylvania, and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.

Seth S. Martin, MD, MHS
From Johns Hopkins Medical Institutions, Baltimore, Maryland; University of Texas Health Science Center, San Antonio, Texas; American College of Physicians, Philadelphia, Pennsylvania, and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.

John E. Cornell, PhD
From Johns Hopkins Medical Institutions, Baltimore, Maryland; University of Texas Health Science Center, San Antonio, Texas; American College of Physicians, Philadelphia, Pennsylvania, and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.

Cynthia D. Mulrow, MD, MSc
From Johns Hopkins Medical Institutions, Baltimore, Maryland; University of Texas Health Science Center, San Antonio, Texas; American College of Physicians, Philadelphia, Pennsylvania, and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.

Eliseo Guallar, MD, DrPH
From Johns Hopkins Medical Institutions, Baltimore, Maryland; University of Texas Health Science Center, San Antonio, Texas; American College of Physicians, Philadelphia, Pennsylvania, and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.

Article, Author, and Disclosure Information
Author, Article, and Disclosure Information
This article was published online first at www.annals.org on 28 April 2015.
  • From Johns Hopkins Medical Institutions, Baltimore, Maryland; University of Texas Health Science Center, San Antonio, Texas; American College of Physicians, Philadelphia, Pennsylvania, and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.

    Financial Support: Dr. Cainzos-Achirica is supported by a research grant from the Spanish Society of Cardiology. Dr. Martin is supported by the Pollin Cardiovascular Prevention Fellowship, the Marie-Josée and Henry R. Kravis endowed fellowship, and a National Institutes of Health training grant (T32 HL007024).

    Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M15-0920.

    Requests for Single Reprints: Eliseo Guallar, MD, DrPH, Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins Bloomberg School of Public Health, 2024 East Monument Street, Room 2-645, Baltimore, MD 21287; e-mail, eguallar@jhu.edu.

    Current Author Addresses: Dr. Cainzos-Achirica: Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins Bloomberg School of Public Health, 2024 East Monument Street, Room 2-644, Baltimore, MD 21287.

    Dr. Martin: Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Carnegie 568A, The Johns Hopkins Hospital, 600 North Wolfe Street, Baltimore, MD 21287.

    Prof. Cornell: Department of Epidemiology and Biostatistics, University of Texas Health Science Center, San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900.

    Dr. Mulrow: American College of Physicians, 190 N. Independence Mall West, Philadelphia, PA 19106-1572.

    Dr. Guallar: Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins Bloomberg School of Public Health, 2024 East Monument Street, Room 2-645, Baltimore, MD 21287.

×
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Jump To
  • Full Article
  • FULL ARTICLE
  • FULL ARTICLE
      1. References
  • Figures
  • Tables
  • Supplements
  • Audio/Video
  • Summary for Patients
  • Clinical Slide Sets
  • CME / MOC
  • Comments
  • Twitter Link
  • Facebook Link
  • Email Link
More
  • LinkedIn Link
In 2003, mutations in the gene encoding the enzyme proprotein convertase subtilisin/kexin type 9 (PCSK9) were identified as genetic causes for familial hypercholesterolemia (1). Investigations soon showed that PCSK9 was a key regulator of low-density lipoprotein (LDL) cholesterol metabolism that promoted the hepatic degradation of LDL receptors and reduced the liver's ability to remove circulating LDL cholesterol. The subsequent characterization of loss-of-function mutations in PCSK9 that result in markedly reduced LDL cholesterol plasma levels set the stage for a new class of lipid-lowering therapies that might prevent cardiovascular disease (CVD) (2).
Drug development progressed rapidly. Within the past 5 years, many monoclonal antibodies, including evolocumab, alirocumab, and bococizumab, were developed as PCSK9 inhibitors that disrupt the interaction between PCSK9 and the LDL receptor. These inhibitors, which are administered subcutaneously in monthly or semimonthly injections, produced striking reductions in LDL cholesterol when compared with placebo or ezetimibe in randomized, controlled trials (3, 4).
In this issue, Navarese and colleagues (5) report the results of a meta-analysis of study-level data from 24 randomized trials that evaluated the effects of PCSK9 antibodies in 10 159 adults with hypercholesterolemia. Most trials involved patients treated with statins who had not met target LDL cholesterol goals, although some focused only on patients who did not tolerate statins. Summary trial data showed that, compared with placebo or ezetimibe control groups, PCSK9 inhibition led to a 47% reduction in LDL cholesterol and a 26% reduction in lipoprotein(a) levels. Data also showed reductions in all-cause mortality rates, cardiovascular mortality rates, and myocardial infarctions, all of which were statistically significant except the cardiovascular mortality outcome (P = 0.084). These results were robust in sensitivity analyses that were stratified by intensity of background statin therapy or by comparator (placebo or ezetimibe). Serious adverse events occurred in approximately 9% and 8% of PCSK9 and comparator groups, respectively. The summary estimates did not include recent results of the Open-Label Study of Long-Term Evaluation Against LDL Cholesterol (OSLER) trials 1 and 2, which studied evolocumab; composite findings of those 2 trials showed a statistically significant reduction in a combined cardiovascular end point with evolocumab (6).
Navarese and colleagues found that the relative reduction of LDL cholesterol levels with PCSK9 inhibitors was similar to or even slightly greater in participants receiving statin treatment than in patients not receiving statin treatment—a finding that highlights the potential value of PCSK9 inhibition as an adjunct to standard therapy. Statins (and ezetimibe) may induce up-regulation of PCSK9, partially attenuating their LDL cholesterol–lowering effect (7, 8). Therefore, PCSK9 inhibitors may be particularly helpful in patients who do not achieve the expected LDL cholesterol reduction with maximally tolerated statins, have very high baseline LDL cholesterol levels (that is, patients with familial hypercholesterolemia, particularly those needing LDL cholesterol apheresis), or have confirmed statin intolerance.
The meta-analysis also found that the comparative LDL cholesterol reduction was smaller when control groups were treated with ezetimibe rather than placebo. A recent large trial, the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT), showed that adding ezetimibe to simvastatin is a safe and effective treatment strategy in high-risk patients over a median of 6 years (9). In addition, compared with the costly injection of monoclonal antibodies, most statins are already available in generic, relatively inexpensive forms, and ezetimibe will go off patent in the near future.
The most remarkable finding of the meta-analysis is the reduction in all-cause mortality rates, cardiovascular mortality rates, and myocardial infarctions with PCSK9 inhibitors. These results, although they are very encouraging, warrant cautious interpretation. Included trials were of small or moderate size and mostly had short follow-up periods. The total number of events was small (for example, the results for all-cause mortality were based on only 40 events), several studies did not report any events at all, and quantitative pooling of rare events remains a challenging task. Moreover, the trials that were summarized were not specifically designed or powered to assess and detect differences in clinical outcomes or rare adverse events. Summaries based on such limited information are tentative at best.
Little is known about the long-term adverse effects of sustained PCSK9 inhibition, including neurocognitive outcomes and diabetes. Basic studies in animal models have suggested that PCSK9 inhibition could impair glucose metabolism (10). Ultimately, trials with long follow-up periods together with real-world experience will be necessary to better characterize the safety profile of PCSK9 inhibition, as well as the patient's tolerance of long-term subcutaneous injections.
Are we entering a new era in lipid-lowering treatment? The current 2013 American College of Cardiology/American Heart Association cholesterol guideline focuses largely on statin therapy and does not establish specific treatment goals. If the efficacy and safety profile of PCSK9 inhibitors is confirmed in long-term trials with a larger number of clinical events and if costs are not prohibitive, clinicians will be able to add PCSK9 inhibitors or ezetimibe to statin therapy and achieve additional LDL cholesterol reductions. Furthermore, with multiple evidence-based safe therapeutic options, it will be critical to establish the optimal sequence and combination of drugs as well as the LDL cholesterol goals that minimize long-term risk in different patient populations. Studies assessing CVD outcomes and cost-effectiveness of different lipid-lowering strategies in populations at different risks for CVD will provide answers to these questions.
The initial clinical trial experience with PCSK9 inhibitors fuels cautious enthusiasm. The meta-analysis by Navarese and colleagues provides important preliminary information on clinical outcomes as the U.S. Food and Drug Administration considers approval of PCSK9 inhibitors for clinical use. Confirmation of these findings in long-term, ongoing, pivotal trials with prespecified primary CVD end points and monitoring of a broad range of adverse events will help establish the role of these novel agents in CVD risk management.

References

  1. Abifadel
    M
    ,  
    Varret
    M
    ,  
    Rabès
    JP
    ,  
    Allard
    D
    ,  
    Ouguerram
    K
    ,  
    Devillers
    M
    ,  
    et al
    Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.
    Nat Genet
    2003
    34
    154
    6
     PubMed
    CrossRef
     PubMed
  2. Cohen
    JC
    ,  
    Boerwinkle
    E
    ,  
    Mosley
    TH
    Jr
    ,  
    Hobbs
    HH
    .  
    Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.
    N Engl J Med
    2006
    354
    1264
    72
     PubMed
    CrossRef
     PubMed
  3. Stein
    EA
    ,  
    Mellis
    S
    ,  
    Yancopoulos
    GD
    ,  
    Stahl
    N
    ,  
    Logan
    D
    ,  
    Smith
    WB
    ,  
    et al
    Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.
    N Engl J Med
    2012
    366
    1108
    18
     PubMed
    CrossRef
     PubMed
  4. Cannon
    CP
    ,  
    Cariou
    B
    ,  
    Blom
    D
    ,  
    McKenney
    JM
    ,  
    Lorenzato
    C
    ,  
    Pordy
    R
    ,  
    et al
    for the ODYSSEY COMBO II Investigators
    Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial.
    Eur Heart J.
    2015
     PubMed
  5. Navarese
    EP
    ,  
    Kołodziejczak
    M
    ,  
    Schulze
    V
    ,  
    Gurbel
    PA
    ,  
    Tantry
    U
    ,  
    Lin
    Y
    ,  
    et al
    Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia. A systematic review and meta-analysis.
    Ann Intern Med
    2015
    163
    40
    51
  6. Sabatine
    MS
    ,  
    Giugliano
    RP
    ,  
    Wiviott
    SD
    ,  
    Raal
    FJ
    ,  
    Blom
    DJ
    ,  
    Robinson
    J
    ,  
    et al
    Open-Label Study of Long-Term Evaluation Against LDL Cholesterol (OSLER) Investigators
    Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.
    N Engl J Med
    2015
    372
    1500
    9
     PubMed
    CrossRef
     PubMed
  7. Davignon
    J
    ,  
    Dubuc
    G
    .  
    Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin-9 (PCSK9) levels.
    Trans Am Clin Climatol Assoc
    2009
    120
    163
    73
     PubMed
     PubMed
  8. Ason
    B
    ,  
    Tep
    S
    ,  
    Davis
    HR
    Jr
    ,  
    Xu
    Y
    ,  
    Tetzloff
    G
    ,  
    Galinski
    B
    ,  
    et al
    Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9.
    J Lipid Res
    2011
    52
    679
    87
     PubMed
    CrossRef
     PubMed
  9. Cannon
    CP
    .  
    on behalf of the IMPROVE-IT investigators
    IMPROVE-IT trial: a comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes [Abstract].
    Circulation
    2014
    130
    2109
  10. Mbikay
    M
    ,  
    Sirois
    F
    ,  
    Mayne
    J
    ,  
    Wang
    GS
    ,  
    Chen
    A
    ,  
    Dewpura
    T
    ,  
    et al
    PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities.
    FEBS Lett
    2010
    584
    701
    6
     PubMed
    CrossRef
     PubMed

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

This feature is available only to Registered Users

Subscribe/Learn More
Submit a Comment

0 Comments

PDF
Not Available
Citations
Citation

Cainzos-Achirica M, Martin SS, Cornell JE, et al. PCSK9 Inhibitors: A New Era in Lipid-Lowering Treatment?. Ann Intern Med. 2015;163:64–65. doi: https://doi.org/10.7326/M15-0920

Download citation file:

  • Ris (Zotero)
  • EndNote
  • BibTex
  • Medlars
  • ProCite
  • RefWorks
  • Reference Manager

© 2019

×
Permissions

Published: Ann Intern Med. 2015;163(1):64-65.

DOI: 10.7326/M15-0920

13 Citations

See Also

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis
View MoreView Less

Related Articles

Effect of Money-Back Guarantees on the Cost-Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors
Annals of Internal Medicine; 168 (12): 896-898
Annals Consult Guys – Measuring Lipids: To Fast or Not to Fast
Annals of Internal Medicine; 166 (2): CG1
Annals for Educators - 17 January 2017
Annals of Internal Medicine; 166 (2): ED2
New Studies Do Not Challenge the American College of Cardiology/American Heart Association Lipid Guidelines
Annals of Internal Medicine; 164 (10): 683-684
View MoreView Less

Journal Club

Review: PCSK9 inhibitors reduce mortality but increase neurocognitive events in hypercholesterolemia
Annals of Internal Medicine; 164 (6): JC31
View MoreView Less

Related Point of Care

Dyslipidemia
Annals of Internal Medicine; 147 (5): ITC9-1
Dyslipidemia
Annals of Internal Medicine; 153 (3): ITC2-1
Dyslipidemia
Annals of Internal Medicine; 167 (11): ITC81-ITC96
View MoreView Less

Related Topics

Cardiology
Coronary Risk Factors
Dyslipidemia

Cardiology, Coronary Risk Factors, Dyslipidemia.

PubMed Articles

Phytosterolemia and γ-glutamyl transferase in adults with parenteral nutrition: Fish versus vegetal lipids: A randomized clinical trial.
Nutrition 2019;
Detailed characterization of Pinus ponderosa sporopollenin by infrared spectroscopy.
Phytochemistry 2019;
View More

Results provided by: PubMed

CME/MOC Activity Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
The Comments Feature Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
link to top

Content

  • Home
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives

Information For

  • Author Info
  • Reviewers
  • Press
  • Readers
  • Institutions / Libraries / Agencies
  • Advertisers

Services

  • Subscribe
  • Renew
  • Alerts
  • Current Issue RSS
  • Latest RSS
  • In the Clinic RSS
  • Reprints & Permissions
  • Contact Us
  • Help
  • About Annals
  • About Mobile
  • Patient Information
  • Teaching Tools
  • Annals in the News
  • Share Your Feedback

Awards and Cover

  • Personae (Cover Photo)
  • Junior Investigator Awards
  • Poetry Prize

Other Resources

  • ACP Online
  • Career Connection
  • ACP Advocate Blog
  • ACP Journal Wise

Follow Annals On

  • Twitter Link
  • Facebook Link
acp link acp
silverchair link silverchair

Copyright © 2019 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
INSTITUTIONAL SIGN IN
Open Athens|Shibboleth|Log In
Annals of Internal Medicine
PURCHASE OPTIONS
Buy This Article|Subscribe
You will be redirected to acponline.org to sign-in to Annals to complete your purchase.
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×